A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer
Androgen-dependent and castration-resistant prostate cancer (PC) is usually sensitive to docetaxel chemotherapy. Nevertheless, docetaxel resistance frequently appears after several cycles of treatment, raising the problem of salvage treatment for docetaxel-resistant PC patients. Although the combina...
Gespeichert in:
| Veröffentlicht in: | Anti-cancer drugs 2010-11, Vol.21 (10), p.927-931 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 931 |
|---|---|
| container_issue | 10 |
| container_start_page | 927 |
| container_title | Anti-cancer drugs |
| container_volume | 21 |
| creator | Dahmani, Ahmed de Plater, Ludmilla Guyader, Charlotte Fontaine, Jean-Jacques Berniard, Aurélie Assayag, Franck Beuzeboc, Philippe Marangoni, Elisabetta Némati, Fariba Poupon, Marie-France Pasik, Christophe Oudard, Stéphane Decaudin, Didier |
| description | Androgen-dependent and castration-resistant prostate cancer (PC) is usually sensitive to docetaxel chemotherapy. Nevertheless, docetaxel resistance frequently appears after several cycles of treatment, raising the problem of salvage treatment for docetaxel-resistant PC patients. Although the combination of docetaxel and estramustine prolongs metastasis-free and overall survival of patients with androgen-independent PC, the use of this modality remains limited in elderly patients or patients with several comorbidities, especially vascular disease or gastrointestinal toxicity, because of unacceptable toxicity including venous thrombosis. The aims of this study were therefore (i) to evaluate the in-vivo efficacy of estramustine combined with docetaxel since initial tumor growth and following the appearance of docetaxel resistance in the androgen-dependent human PC xenograft PAC120, and (ii) to evaluate the efficacy of estramustine in six human androgen-independent PC models derived from PAC120. In docetaxel-resistant tumor-bearing mice, estramustine alone induced a TGD2 of 18 days, whereas the combination of docetaxel and estramustine induced a TGD2 of 50 days (P |
| doi_str_mv | 10.1097/CAD.0b013e32833db887 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_CAD_0b013e32833db887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20827173</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3516-406ef9ea2b0910f219fdc0b1947cb54f415657ab877fd61beb701158dde56e9b3</originalsourceid><addsrcrecordid>eNpdkNtq3DAQhkVpabZp36AUvYDTGcu2rMtl0xMEcpNcGx3GXTXyAUkmaZ--WtKkkKthfvi_GT7GPiJcICj5-bC_vAADKEjUvRDO9L18xXbYSFG1ssHXbAeqVVWjpDhj71L6BQAlF2_ZWQ19LVGKHbvb8zWSDX72VgeejxT1Slv2lid7JLcF4sua_eT_-Pknd4ulrB8o8DVsiVPKUU9byn4mrt1UKKck-2Xmfi7kJWWdiVs9W4rv2ZtRh0Qf_s1zdvv1y83he3V1_e3HYX9VWdFiVzXQ0ahI1wYUwlijGp0Fg6qR1rTN2GDbtVKbXsrRdWjISEBse-eo7UgZcc6aR64t91OkcVijn3T8PSAMJ3dDcTe8dFdqnx5r62Ymcs-lJ1n_ufdLyBTTXdjuKQ5H0iEfh2IXsEdR1YDln7JVp6gTfwF2vX4H</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Dahmani, Ahmed ; de Plater, Ludmilla ; Guyader, Charlotte ; Fontaine, Jean-Jacques ; Berniard, Aurélie ; Assayag, Franck ; Beuzeboc, Philippe ; Marangoni, Elisabetta ; Némati, Fariba ; Poupon, Marie-France ; Pasik, Christophe ; Oudard, Stéphane ; Decaudin, Didier</creator><creatorcontrib>Dahmani, Ahmed ; de Plater, Ludmilla ; Guyader, Charlotte ; Fontaine, Jean-Jacques ; Berniard, Aurélie ; Assayag, Franck ; Beuzeboc, Philippe ; Marangoni, Elisabetta ; Némati, Fariba ; Poupon, Marie-France ; Pasik, Christophe ; Oudard, Stéphane ; Decaudin, Didier</creatorcontrib><description>Androgen-dependent and castration-resistant prostate cancer (PC) is usually sensitive to docetaxel chemotherapy. Nevertheless, docetaxel resistance frequently appears after several cycles of treatment, raising the problem of salvage treatment for docetaxel-resistant PC patients. Although the combination of docetaxel and estramustine prolongs metastasis-free and overall survival of patients with androgen-independent PC, the use of this modality remains limited in elderly patients or patients with several comorbidities, especially vascular disease or gastrointestinal toxicity, because of unacceptable toxicity including venous thrombosis. The aims of this study were therefore (i) to evaluate the in-vivo efficacy of estramustine combined with docetaxel since initial tumor growth and following the appearance of docetaxel resistance in the androgen-dependent human PC xenograft PAC120, and (ii) to evaluate the efficacy of estramustine in six human androgen-independent PC models derived from PAC120. In docetaxel-resistant tumor-bearing mice, estramustine alone induced a TGD2 of 18 days, whereas the combination of docetaxel and estramustine induced a TGD2 of 50 days (P<0.05) with no significantly different overall survival of mice treated by docetaxel and estramustine since day 1 or since the onset of resistance to docetaxel. Among the six human androgen-independent tumors treated with estramustine alone, two highly sensitive models, two intermediate responding tumors, and two resistant models were observed. Altogether, these results suggest that estramustine should be combined with docetaxel in PC patients, but the use of this treatment could be limited, particularly in elderly patients, to docetaxel-resistant cases.</description><identifier>ISSN: 0959-4973</identifier><identifier>EISSN: 1473-5741</identifier><identifier>DOI: 10.1097/CAD.0b013e32833db887</identifier><identifier>PMID: 20827173</identifier><language>eng</language><publisher>England: Lippincott Williams & Wilkins, Inc</publisher><subject>Aged ; Animals ; Antineoplastic Agents, Hormonal - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Comorbidity ; Drug Evaluation, Preclinical ; Drug Resistance, Neoplasm ; Estramustine - pharmacology ; Gastrointestinal Diseases - epidemiology ; Humans ; Male ; Mice ; Mice, Nude ; Neoplasms, Hormone-Dependent - blood ; Neoplasms, Hormone-Dependent - drug therapy ; Neoplasms, Hormone-Dependent - epidemiology ; Orchiectomy ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - epidemiology ; Survival Rate ; Taxoids - pharmacology ; Vascular Diseases - epidemiology ; Venous Thrombosis - chemically induced ; Xenograft Model Antitumor Assays</subject><ispartof>Anti-cancer drugs, 2010-11, Vol.21 (10), p.927-931</ispartof><rights>2010 Lippincott Williams & Wilkins, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3516-406ef9ea2b0910f219fdc0b1947cb54f415657ab877fd61beb701158dde56e9b3</citedby><cites>FETCH-LOGICAL-c3516-406ef9ea2b0910f219fdc0b1947cb54f415657ab877fd61beb701158dde56e9b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20827173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dahmani, Ahmed</creatorcontrib><creatorcontrib>de Plater, Ludmilla</creatorcontrib><creatorcontrib>Guyader, Charlotte</creatorcontrib><creatorcontrib>Fontaine, Jean-Jacques</creatorcontrib><creatorcontrib>Berniard, Aurélie</creatorcontrib><creatorcontrib>Assayag, Franck</creatorcontrib><creatorcontrib>Beuzeboc, Philippe</creatorcontrib><creatorcontrib>Marangoni, Elisabetta</creatorcontrib><creatorcontrib>Némati, Fariba</creatorcontrib><creatorcontrib>Poupon, Marie-France</creatorcontrib><creatorcontrib>Pasik, Christophe</creatorcontrib><creatorcontrib>Oudard, Stéphane</creatorcontrib><creatorcontrib>Decaudin, Didier</creatorcontrib><title>A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer</title><title>Anti-cancer drugs</title><addtitle>Anticancer Drugs</addtitle><description>Androgen-dependent and castration-resistant prostate cancer (PC) is usually sensitive to docetaxel chemotherapy. Nevertheless, docetaxel resistance frequently appears after several cycles of treatment, raising the problem of salvage treatment for docetaxel-resistant PC patients. Although the combination of docetaxel and estramustine prolongs metastasis-free and overall survival of patients with androgen-independent PC, the use of this modality remains limited in elderly patients or patients with several comorbidities, especially vascular disease or gastrointestinal toxicity, because of unacceptable toxicity including venous thrombosis. The aims of this study were therefore (i) to evaluate the in-vivo efficacy of estramustine combined with docetaxel since initial tumor growth and following the appearance of docetaxel resistance in the androgen-dependent human PC xenograft PAC120, and (ii) to evaluate the efficacy of estramustine in six human androgen-independent PC models derived from PAC120. In docetaxel-resistant tumor-bearing mice, estramustine alone induced a TGD2 of 18 days, whereas the combination of docetaxel and estramustine induced a TGD2 of 50 days (P<0.05) with no significantly different overall survival of mice treated by docetaxel and estramustine since day 1 or since the onset of resistance to docetaxel. Among the six human androgen-independent tumors treated with estramustine alone, two highly sensitive models, two intermediate responding tumors, and two resistant models were observed. Altogether, these results suggest that estramustine should be combined with docetaxel in PC patients, but the use of this treatment could be limited, particularly in elderly patients, to docetaxel-resistant cases.</description><subject>Aged</subject><subject>Animals</subject><subject>Antineoplastic Agents, Hormonal - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Comorbidity</subject><subject>Drug Evaluation, Preclinical</subject><subject>Drug Resistance, Neoplasm</subject><subject>Estramustine - pharmacology</subject><subject>Gastrointestinal Diseases - epidemiology</subject><subject>Humans</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Neoplasms, Hormone-Dependent - blood</subject><subject>Neoplasms, Hormone-Dependent - drug therapy</subject><subject>Neoplasms, Hormone-Dependent - epidemiology</subject><subject>Orchiectomy</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - epidemiology</subject><subject>Survival Rate</subject><subject>Taxoids - pharmacology</subject><subject>Vascular Diseases - epidemiology</subject><subject>Venous Thrombosis - chemically induced</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0959-4973</issn><issn>1473-5741</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkNtq3DAQhkVpabZp36AUvYDTGcu2rMtl0xMEcpNcGx3GXTXyAUkmaZ--WtKkkKthfvi_GT7GPiJcICj5-bC_vAADKEjUvRDO9L18xXbYSFG1ssHXbAeqVVWjpDhj71L6BQAlF2_ZWQ19LVGKHbvb8zWSDX72VgeejxT1Slv2lid7JLcF4sua_eT_-Pknd4ulrB8o8DVsiVPKUU9byn4mrt1UKKck-2Xmfi7kJWWdiVs9W4rv2ZtRh0Qf_s1zdvv1y83he3V1_e3HYX9VWdFiVzXQ0ahI1wYUwlijGp0Fg6qR1rTN2GDbtVKbXsrRdWjISEBse-eo7UgZcc6aR64t91OkcVijn3T8PSAMJ3dDcTe8dFdqnx5r62Ymcs-lJ1n_ufdLyBTTXdjuKQ5H0iEfh2IXsEdR1YDln7JVp6gTfwF2vX4H</recordid><startdate>201011</startdate><enddate>201011</enddate><creator>Dahmani, Ahmed</creator><creator>de Plater, Ludmilla</creator><creator>Guyader, Charlotte</creator><creator>Fontaine, Jean-Jacques</creator><creator>Berniard, Aurélie</creator><creator>Assayag, Franck</creator><creator>Beuzeboc, Philippe</creator><creator>Marangoni, Elisabetta</creator><creator>Némati, Fariba</creator><creator>Poupon, Marie-France</creator><creator>Pasik, Christophe</creator><creator>Oudard, Stéphane</creator><creator>Decaudin, Didier</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201011</creationdate><title>A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer</title><author>Dahmani, Ahmed ; de Plater, Ludmilla ; Guyader, Charlotte ; Fontaine, Jean-Jacques ; Berniard, Aurélie ; Assayag, Franck ; Beuzeboc, Philippe ; Marangoni, Elisabetta ; Némati, Fariba ; Poupon, Marie-France ; Pasik, Christophe ; Oudard, Stéphane ; Decaudin, Didier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3516-406ef9ea2b0910f219fdc0b1947cb54f415657ab877fd61beb701158dde56e9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Animals</topic><topic>Antineoplastic Agents, Hormonal - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Comorbidity</topic><topic>Drug Evaluation, Preclinical</topic><topic>Drug Resistance, Neoplasm</topic><topic>Estramustine - pharmacology</topic><topic>Gastrointestinal Diseases - epidemiology</topic><topic>Humans</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Neoplasms, Hormone-Dependent - blood</topic><topic>Neoplasms, Hormone-Dependent - drug therapy</topic><topic>Neoplasms, Hormone-Dependent - epidemiology</topic><topic>Orchiectomy</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - epidemiology</topic><topic>Survival Rate</topic><topic>Taxoids - pharmacology</topic><topic>Vascular Diseases - epidemiology</topic><topic>Venous Thrombosis - chemically induced</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dahmani, Ahmed</creatorcontrib><creatorcontrib>de Plater, Ludmilla</creatorcontrib><creatorcontrib>Guyader, Charlotte</creatorcontrib><creatorcontrib>Fontaine, Jean-Jacques</creatorcontrib><creatorcontrib>Berniard, Aurélie</creatorcontrib><creatorcontrib>Assayag, Franck</creatorcontrib><creatorcontrib>Beuzeboc, Philippe</creatorcontrib><creatorcontrib>Marangoni, Elisabetta</creatorcontrib><creatorcontrib>Némati, Fariba</creatorcontrib><creatorcontrib>Poupon, Marie-France</creatorcontrib><creatorcontrib>Pasik, Christophe</creatorcontrib><creatorcontrib>Oudard, Stéphane</creatorcontrib><creatorcontrib>Decaudin, Didier</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Anti-cancer drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dahmani, Ahmed</au><au>de Plater, Ludmilla</au><au>Guyader, Charlotte</au><au>Fontaine, Jean-Jacques</au><au>Berniard, Aurélie</au><au>Assayag, Franck</au><au>Beuzeboc, Philippe</au><au>Marangoni, Elisabetta</au><au>Némati, Fariba</au><au>Poupon, Marie-France</au><au>Pasik, Christophe</au><au>Oudard, Stéphane</au><au>Decaudin, Didier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer</atitle><jtitle>Anti-cancer drugs</jtitle><addtitle>Anticancer Drugs</addtitle><date>2010-11</date><risdate>2010</risdate><volume>21</volume><issue>10</issue><spage>927</spage><epage>931</epage><pages>927-931</pages><issn>0959-4973</issn><eissn>1473-5741</eissn><abstract>Androgen-dependent and castration-resistant prostate cancer (PC) is usually sensitive to docetaxel chemotherapy. Nevertheless, docetaxel resistance frequently appears after several cycles of treatment, raising the problem of salvage treatment for docetaxel-resistant PC patients. Although the combination of docetaxel and estramustine prolongs metastasis-free and overall survival of patients with androgen-independent PC, the use of this modality remains limited in elderly patients or patients with several comorbidities, especially vascular disease or gastrointestinal toxicity, because of unacceptable toxicity including venous thrombosis. The aims of this study were therefore (i) to evaluate the in-vivo efficacy of estramustine combined with docetaxel since initial tumor growth and following the appearance of docetaxel resistance in the androgen-dependent human PC xenograft PAC120, and (ii) to evaluate the efficacy of estramustine in six human androgen-independent PC models derived from PAC120. In docetaxel-resistant tumor-bearing mice, estramustine alone induced a TGD2 of 18 days, whereas the combination of docetaxel and estramustine induced a TGD2 of 50 days (P<0.05) with no significantly different overall survival of mice treated by docetaxel and estramustine since day 1 or since the onset of resistance to docetaxel. Among the six human androgen-independent tumors treated with estramustine alone, two highly sensitive models, two intermediate responding tumors, and two resistant models were observed. Altogether, these results suggest that estramustine should be combined with docetaxel in PC patients, but the use of this treatment could be limited, particularly in elderly patients, to docetaxel-resistant cases.</abstract><cop>England</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>20827173</pmid><doi>10.1097/CAD.0b013e32833db887</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-4973 |
| ispartof | Anti-cancer drugs, 2010-11, Vol.21 (10), p.927-931 |
| issn | 0959-4973 1473-5741 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_CAD_0b013e32833db887 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Aged Animals Antineoplastic Agents, Hormonal - pharmacology Antineoplastic Combined Chemotherapy Protocols - pharmacology Comorbidity Drug Evaluation, Preclinical Drug Resistance, Neoplasm Estramustine - pharmacology Gastrointestinal Diseases - epidemiology Humans Male Mice Mice, Nude Neoplasms, Hormone-Dependent - blood Neoplasms, Hormone-Dependent - drug therapy Neoplasms, Hormone-Dependent - epidemiology Orchiectomy Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - epidemiology Survival Rate Taxoids - pharmacology Vascular Diseases - epidemiology Venous Thrombosis - chemically induced Xenograft Model Antitumor Assays |
| title | A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T00%3A17%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20preclinical%20therapeutic%20schedule%20optimizing%20docetaxel%20plus%20estramustine%20administration%20in%20prostate%20cancer&rft.jtitle=Anti-cancer%20drugs&rft.au=Dahmani,%20Ahmed&rft.date=2010-11&rft.volume=21&rft.issue=10&rft.spage=927&rft.epage=931&rft.pages=927-931&rft.issn=0959-4973&rft.eissn=1473-5741&rft_id=info:doi/10.1097/CAD.0b013e32833db887&rft_dat=%3Cpubmed_cross%3E20827173%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/20827173&rfr_iscdi=true |